Peptide News
A static news aggregator refreshed from FDA MedWatch, PubMed, and ClinicalTrials.gov so the site can surface real signal without inventing headlines.
Latest sync: Oct 3, 2026, 4:34 PM. This page favors official and public primary sources over generic news scraping.
Display order is chronological from newest to oldest; future-dated or recently indexed items are pushed to the end.
Status: fallback • Conflicting news source items canonicalized to FDA.gov https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/greenwich-rx-issues-voluntary-nationwide-recall-compounded-glutathione-due-elevated-endotoxin-levels: publishedAt, publishedLabel, sourceType
Status: live
Status: live
EASL-EASD-EASO Guidance for the Use of Resmetirom and Semaglutide as MASH-Targeted Therapy.
J Hepatol • Semaglutide • Journal Article
What moved most recently
Newly surfaced trials, FDA action, and PubMed additions sorted with the newest items first.
Newest peptide and GLP-1 updates
A rolling stream of the most recent official and public-source items in the tracker. Future-dated PubMed indexing artifacts stay at the bottom.
EASL-EASD-EASO Guidance for the Use of Resmetirom and Semaglutide as MASH-Targeted Therapy.
J Hepatol • Semaglutide • Journal Article
Detection and Excretion Profile of Retatrutide in Human Plasma and Urine by LC-HRMS: Implications for Antidoping Analysis.
Rapid Commun Mass Spectrom • Retatrutide • Journal Article
A Research Study Investigating How Adults With Overweight or Obesity, With or Without Type 2 Diabetes, Tolerate Switching to a New Treatment (Zenagamtide) From Their Current Semaglutide Medication
NOT_YET_RECRUITING • Novo Nordisk A/S
Tirzepatide in Obesity-Driven Endometrial Cancer
RECRUITING • UNC Lineberger Comprehensive Cancer Center
SYNCHRONIZE®-START- A Study to Test Whether Survodutide Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose Weight
NOT_YET_RECRUITING • Boehringer Ingelheim
Response to Semaglutide in Non-diabetic Obese Patients With Varying Degrees of Insulin Resistance
COMPLETED • ETH Zurich
GLP-1s to Enhance Lasting Optimal Weight
ACTIVE_NOT_RECRUITING • Wake Forest University Health Sciences
FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss
FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss
Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)
ACTIVE_NOT_RECRUITING • Eli Lilly and Company
Incretin-based injectable strategies versus intensified insulin for treatment intensification and simplification in type 2 diabetes: a systematic review and meta-analysis.
J Diabetes Metab Disord • Tirzepatide • Journal Article
A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain
ACTIVE_NOT_RECRUITING • Eli Lilly and Company
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)
ACTIVE_NOT_RECRUITING • Eli Lilly and Company
BPC 157 in Rodent Ischemia-Reperfusion Injury: A Critical Review of Preclinical Evidence.
Int J Mol Sci • BPC-157 • Journal Article
Centric Compounding Issues Nationwide Recall of Glutathione, Myer’s Cocktail, and Tri-Immune Boost Due to Elevated Endotoxin Levels
FOR IMMEDIATE RELEASE – 9/9/2026 – Houston, Texas, Centric Compounding is voluntarily recalling 6 lots of Glutathione 200mg/mL, Myer’s Cocktail, and Tri-Immune Boost injectable vials to the consumer level. The products have been found to be compounded with a Glutathione API containing elevated endot
Efficient Expression of Small Molecule Bioactive Peptides in Bacillus licheniformis.
Appl Biochem Biotechnol • BPC-157 • Journal Article
Clinical practice patterns and unmet needs in the use of GLP-1 receptor agonists in sleep medicine: A pan-European survey performed in the European sleep apnoea database network.
Pulmonology • Tirzepatide • Journal Article
Peptides in Regenerative Medicine: A Comprehensive Review of Clinical Applications in Tissue Repair and Chronic Pain Management.
Curr Pain Headache Rep • BPC-157 • Journal Article
Hunger pain and its reduction; qualitative insight from people with schizophrenia on semaglutide.
Int J Qual Stud Health Well-being • Semaglutide • Journal Article
Design, synthesis, and stability evaluation of semaglutide-derived lactam-stapled peptide scaffolds for GLP-1R targeting.
J Enzyme Inhib Med Chem • Semaglutide • Journal Article
Peptide Supplements and Their Therapeutic Applications in Sports Medicine.
Am J Sports Med • BPC-157 • Journal Article
One receptor, two opposite approaches: efficacy and tolerability of GIPR agonism and antagonism in obesity pharmacotherapy.
Appetite • Tirzepatide • Journal Article
Development and validation of a multiplexed LC-HRMS method for nine GLP-1 receptor agonists and its pharmaceutical application.
J Chromatogr A • Retatrutide • Journal Article
Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV
RECRUITING • Massachusetts General Hospital
Body Composition and Adipose Tissue in HIV
TERMINATED • Columbia University
Tesamorelin for Reduction of Liver Fat in Adults With Fatty Liver Disease (Mock Study)
RECRUITING • Hudson Biotech
FDA.gov
Regulatory and enforcement signal from FDA feeds that touch peptides, GLP-1s, compounding, and obesity.
ClinicalTrials.gov
Recently updated or newly visible clinical studies tied to tracked compounds and obesity-adjacent programs.
PubMed
Recent research hits for tracked peptide and GLP-1 terms, with reviews and meta-analyses surfaced when available.
This page is built from a generated JSON snapshot refreshed by scheduled syncs, not from a live browser request. FDA items come from RSS feeds, PubMed items come from NCBI utilities, and study updates come from the ClinicalTrials.gov API. The page is date-ordered for readability, while the underlying generator still scores relevance for homepage surfacing and future editorial modules.